Treatment of behcet's disease with levamisole

Ayed, K.; Ayed, H Ben

doi:10.1002/art.1780250621

Cited by 12 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the other study, which had a similar design, patients using penicillin and colchicine had small to moderate effect sizes for the improvement in mucocutaneous lesions, when compared to those receiving only colchicines 67. Other antibiotics such as minocycline68 and azithromycin,69 and an antihelminthic drug, levamisole,70 have been shown to provide some benefit.…”

Section: Resultsmentioning

confidence: 98%

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease

Hatemi

Silman

Bang

et al. 2009

Annals of the Rheumatic Diseases

183

117

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease

Hatemi

Silman

Bang

et al. 2009

Annals of the Rheumatic Diseases

183

117

View full text Add to dashboard Cite

show abstract

“…Speculation about an infectious genesis of BS has led to the use of antimicrobial and antiviral agents for its treatment. Beneficial effects have been shown only for anti‐bacterial, and one anti‐helminitc drug [Hamza et al, 1982], although the recently introduced IFN‐α may be perceived as an antiviral agent. There are, however, no convincing data linking the antiviral properties of IFN‐α to a therapeutic effect in BS.…”

Section: Other Drugsmentioning

confidence: 99%

Current management of Behçet's syndrome

Nowatzky

Yazıcı

2011

Drug Development Research

View full text Add to dashboard Cite

Behçet's syndrome (BS), or Behçet's disease (BD), is a multisystem inflammatory disorder that mainly affects population clusters along the Old Silk Road; however, it has been reported worldwide. The disease is currently classified as a vasculitis, characterized by sporadic outbreaks. The hallmarks of BS are recurrent, painful oral ulcers. Skin, eyes, central nervous system (CNS), gastrointestinal tract (GI) tract, and other organs may also be involved. CNS, GI, and major vascular involvement can be life‐threatening, and uveitis may lead to blindness. Immunosuppressive and immunomodulatory treatment is the mainstay of therapy for this inflammatory disease. Whereas the most frequently used agents for the treatment of BS have been corticosteroids, colchicine, and azathioprine, the introduction of anti‐tumor necrosis factor (TNF) agents and interferon‐α (IFN‐α) has begun to revolutionize the treatment of Behçet's eye disease and the management of other major organ manifestations. Data from randomized controlled trials (RCTs) showing beneficial effects for some of its disease manifestations are available for azathioprine, colchicine, cyclosporine, etanercept, IFN‐α depot‐methylprednisolone, and others. Currently, an evidence‐based approach to the management of BS is possible only for eye, mucocutaneous, and joint involvement, whereas recommendations for the treatment of gastrointestinal, neurological, and vascular disease remain based on expert opinion. Drug Dev Res 72:647–656, 2011. © 2011 Wiley Periodicals, Inc.

show abstract

Behçet’s Syndrome: From Aetiology to Treatment

Powell

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Treatment of behcet's disease with levamisole

Cited by 12 publications

References 1 publication

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease

Current management of Behçet's syndrome

Behçet’s Syndrome: From Aetiology to Treatment

Contact Info

Product

Resources

About